AU2019299676A1 - Combination therapy with CGRP antagonists and Clostridial derivatives - Google Patents

Combination therapy with CGRP antagonists and Clostridial derivatives Download PDF

Info

Publication number
AU2019299676A1
AU2019299676A1 AU2019299676A AU2019299676A AU2019299676A1 AU 2019299676 A1 AU2019299676 A1 AU 2019299676A1 AU 2019299676 A AU2019299676 A AU 2019299676A AU 2019299676 A AU2019299676 A AU 2019299676A AU 2019299676 A1 AU2019299676 A1 AU 2019299676A1
Authority
AU
Australia
Prior art keywords
dose
weeks
administered subcutaneously
months
cgrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019299676A
Other languages
English (en)
Inventor
Andrew M. Blumenfeld
Mitchell F. Brin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals International Ltd
Original Assignee
Allergan Pharmaceuticals International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Pharmaceuticals International Ltd filed Critical Allergan Pharmaceuticals International Ltd
Publication of AU2019299676A1 publication Critical patent/AU2019299676A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
AU2019299676A 2018-07-05 2019-07-04 Combination therapy with CGRP antagonists and Clostridial derivatives Pending AU2019299676A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694358P 2018-07-05 2018-07-05
US62/694,358 2018-07-05
PCT/IB2019/055704 WO2020008402A2 (fr) 2018-07-05 2019-07-04 Polythérapie avec des antagonistes du cgrp et des dérivés de clostridium

Publications (1)

Publication Number Publication Date
AU2019299676A1 true AU2019299676A1 (en) 2021-01-28

Family

ID=67957184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019299676A Pending AU2019299676A1 (en) 2018-07-05 2019-07-04 Combination therapy with CGRP antagonists and Clostridial derivatives

Country Status (6)

Country Link
US (2) US20200030415A1 (fr)
EP (2) EP3817766A2 (fr)
AU (1) AU2019299676A1 (fr)
CA (1) CA3105778A1 (fr)
TW (1) TW202019459A (fr)
WO (1) WO2020008402A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
CA3127328A1 (fr) * 2019-01-20 2020-07-23 Biohaven Pharmaceutical Holding Company Ltd. Antagonistes du cgrp pour le traitement d'une migraine intense
US20210130445A1 (en) * 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders
WO2021005494A1 (fr) * 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Antagonistes du cgrp et dérivés de clostridiales pour le traitement de troubles neuropsychiatriques et neurologiques
AU2021240083A1 (en) * 2020-03-18 2022-10-20 Revance Therapeutics, Inc. Injectable botulinum toxin methods for treating headaches
EP4125899A1 (fr) * 2020-03-29 2023-02-08 Biohaven Pharmaceutical Ireland DAC Traitement préventif de la migraine
IT202000029474A1 (it) * 2020-12-03 2022-06-03 Alberto Chiarugi Trattamento dei disturbi emotivi con antagonisti recettoriali
WO2023055758A1 (fr) * 2021-09-29 2023-04-06 Pfizer Ireland Pharmaceuticals Traitement préventif de la migraine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US8717572B2 (en) 2007-06-12 2014-05-06 Hewlett-Packard Development Company, L.P. Spectrophotometer
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
CA2735242C (fr) 2009-03-13 2017-01-24 Birgitte P.S. Jacky Cellules utiles pour des essais d'activite de la toxine botulinique de serotype a bases sur l'immunologie
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
US20180092899A1 (en) * 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
CA3127328A1 (fr) * 2019-01-20 2020-07-23 Biohaven Pharmaceutical Holding Company Ltd. Antagonistes du cgrp pour le traitement d'une migraine intense

Also Published As

Publication number Publication date
EP4302828A2 (fr) 2024-01-10
CA3105778A1 (fr) 2020-01-09
WO2020008402A2 (fr) 2020-01-09
US20200030415A1 (en) 2020-01-30
EP3817766A2 (fr) 2021-05-12
US20230105611A1 (en) 2023-04-06
WO2020008402A3 (fr) 2020-03-05
TW202019459A (zh) 2020-06-01
EP4302828A3 (fr) 2024-01-17

Similar Documents

Publication Publication Date Title
US20230105611A1 (en) Combination therapy with cgrp antagonists and clostridial derivatives
US9238061B2 (en) Botulinum toxin treatment of anxiety and bipolar disorders
US8609112B2 (en) Botulinum toxin treatments of depression
US8609113B2 (en) Botulinum toxin treatments of depression
JP5425622B2 (ja) 少なくとも１種のボツリヌス神経毒素及び少なくとも１種の鎮静剤誘導体の、治療上の、同時、分離、又は、順次的な使用
JP5739908B2 (ja) 血管形成関連の眼疾患の処置のための組成物および方法
US20220340650A1 (en) Combination therapy with cgrp antagonists
EA013591B1 (ru) Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd)
US20210121541A1 (en) CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
US20140147500A1 (en) Preparation and Use of Combination Enzyme and Gastrointestinal Modulator Delivery Systems
WO2011087066A1 (fr) Produit pharmaceutique destiné au traitement prophylactique ou thérapeutique de troubles accompagnés d'une angiogenèse oculaire et/ou d'une perméabilité vasculaire oculaire supérieure à la normale
US8697090B2 (en) Method of treating persistent genital arousal disorder with a neurotoxin
US20210130445A1 (en) CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders
US20210128724A1 (en) Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
KR101467841B1 (ko) 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물
JP5189240B2 (ja) ５−ヒドロキシトリプタミン１ａレセプター活性増強化合物を用いる運動症状の変動の治療
KR102489109B1 (ko) 아세틸콜린 수용체 변이 유전자를 유효성분으로 포함하는 근긴장 이상증 치료용 조성물
US20230210963A1 (en) Injectable botulinum toxin methos for treating headaches